FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups

FDA expands the indication of Vascepa (icosapent ethyl) capsules to reduce the risk of cardiovascular events as an adjunct to maximally tolerated statin therapy in high-risk adult patients with elevated triglyceride levels. It is a fish oil-derived omega-3 fatty acid product indicated to reduce the

Source: FDA Center for Drug Evaluation and Research - What's New - December 13, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news